In a recent bid Adverum Biotechnologies Inc. [ADVM] faced a contemporary bid of $11.71 yielding a 13.14% incline where 1.07 million shares have exchanged hands over the last week. ADVM amount got a boost by 4.09% or $0.46 versus $11.25 at the end of the prior session. This change led market cap to move at 1.11B, putting the price 113.30% below the 52-week high and -56.60% above the 52-week low. The company’s stock has a normal trading capacity of 1.07 million shares while the relative volume is 0.81.

On 15, September 2020, Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science. According to news published on Yahoo Finance, Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the company as vice president, process development, reporting into Adverum’s chief technology officer Angela Thedinga.

Analyst Birdseye View:

The most recent analyst activity for Adverum Biotechnologies Inc. [NASDAQ:ADVM] stock was on May 13, 2020, when it was Initiated with an Outperform rating from RBC Capital Mkts, which also raised its 12-month price target on the stock to $24. On May 05, 2020, SunTrust Upgrade a Buy rating and boosted its price target on this stock from $13 to $21. On April 28, 2020, Goldman Initiated a Buy rating and increased its price target to $17. On March 16, 2020, SVB Leerink Initiated an Outperform rating and increased its price target to $17. On February 10, 2020, Chardan Capital Markets Upgrade a Buy rating and boosted its amount on this stock to $20. On February 10, 2020, Cantor Fitzgerald Upgrade an Overweight rating and boosted its target amount on this stock from $8 to $21. On October 15, 2019 Chardan Capital Markets Reiterated a Neutral rating and elevated its amount target to $10.

In the past 52 weeks of trading, this stock has oscillated between a low of $5.49 and a peak of $26.98. Right now, according to Wall Street analyst the average 12-month amount target is $28.43. At the most recent market close, shares of Adverum Biotechnologies Inc. [NASDAQ:ADVM] were valued at $11.71.


This publicly-traded organization’s revenue is $2,193 per employee, while its income is -$565,667 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -29.57, -34.29, -33.53 and -31.87 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 15.64 and the whole liability to whole assets at 14.57. It shows enduring liability to the whole principal at 13.65 and enduring liability to assets at 0.13 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 11.36 points at 1st support level, the second support level is making up to 11.01. But as of 1st resistance point, this stock is sitting at 11.94 and at 12.17 for 2nd resistance point.

Adverum Biotechnologies Inc. [ADVM] reported its earnings at -$0.36 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.28/share signifying the difference of -0.08 and -28.60% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.31 calling estimates for -$0.27/share with the difference of -0.04 depicting the surprise of -14.80%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Adverum Biotechnologies Inc. [NASDAQ:ADVM] is 13.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 8.55. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2,953.82 and it’s amount to book ratio is 4.43.

Insider Stories

The most recent insider trade was by Soparkar Peter, Chief Legal Officer, and it was the purchase of 7692.0 shares on Aug 17. Fischer Laurent, the CEO and Director, completed a purchase of 7692.0 shares on Aug 17. On Jul 20, Gasmi Mehdi, Director, completed a sale of 5000.0 shares.